H-Index & Metrics Best Publications

H-Index & Metrics

Discipline name H-index Citations Publications World Ranking National Ranking
Medicine D-index 170 Citations 114,244 1,449 World Ranking 194 National Ranking 129

Overview

What is she best known for?

The fields of study she is best known for:

  • Internal medicine
  • Cancer
  • Chemotherapy

Susan O'Brien mainly investigates Internal medicine, Gastroenterology, Leukemia, Surgery and Immunology. Her Oncology research extends to Internal medicine, which is thematically connected. Her Oncology study incorporates themes from Cancer, Survival analysis and Refractory.

The Gastroenterology study combines topics in areas such as Blastic Phase, Cytarabine, Salvage therapy, Philadelphia chromosome and Acute lymphocytic leukemia. Susan O'Brien has included themes like Cancer research, Myeloid leukemia, Myelodysplastic syndromes and Pathology in her Leukemia study. Her Chronic lymphocytic leukemia study combines topics from a wide range of disciplines, such as Fludarabine and Rituximab.

Her most cited work include:

  • National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment (1814 citations)
  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia (1539 citations)
  • Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias (1448 citations)

What are the main themes of her work throughout her whole career to date?

Susan O'Brien mostly deals with Internal medicine, Oncology, Gastroenterology, Surgery and Chronic lymphocytic leukemia. Her Internal medicine study frequently involves adjacent topics like Immunology. She combines subjects such as Cancer and Imatinib, Myeloid leukemia, Dasatinib with her study of Oncology.

Her studies in Gastroenterology integrate themes in fields like Phases of clinical research, Imatinib mesylate, Cytarabine, Neutropenia and Acute lymphocytic leukemia. The various areas that Susan O'Brien examines in her Chronic lymphocytic leukemia study include Cancer research, Alemtuzumab and Bruton's tyrosine kinase. Susan O'Brien interconnects Survival rate, Pathology, Refractory and Myeloid in the investigation of issues within Leukemia.

She most often published in these fields:

  • Internal medicine (78.67%)
  • Oncology (34.14%)
  • Gastroenterology (32.90%)

What were the highlights of her more recent work (between 2016-2021)?

  • Internal medicine (78.67%)
  • Oncology (34.14%)
  • Chronic lymphocytic leukemia (26.44%)

In recent papers she was focusing on the following fields of study:

Susan O'Brien focuses on Internal medicine, Oncology, Chronic lymphocytic leukemia, Ibrutinib and In patient. Her Internal medicine research focuses on subjects like Gastroenterology, which are linked to Survival rate. Her Oncology study combines topics in areas such as Cyclophosphamide, Fludarabine, Chemoimmunotherapy and Blinatumomab, Lymphoblastic Leukemia.

In Chronic lymphocytic leukemia, Susan O'Brien works on issues like Cancer research, which are connected to B cell. Her biological study deals with issues like Discontinuation, which deal with fields such as Adverse effect. Her Leukemia research integrates issues from Hematology and Lymphoma.

Between 2016 and 2021, her most popular works were:

  • iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
  • Single-Agent Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience (201 citations)
  • Single-Agent Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience (201 citations)

In her most recent research, the most cited papers focused on:

  • Internal medicine
  • Cancer
  • Chemotherapy

Her primary areas of study are Internal medicine, Ibrutinib, Chronic lymphocytic leukemia, Oncology and Leukemia. Internal medicine and Gastroenterology are frequently intertwined in her study. Her Ibrutinib research is multidisciplinary, incorporating elements of Progressive disease, Surgery, Hematology, Ofatumumab and [email protected]

Her study looks at the relationship between Chronic lymphocytic leukemia and fields such as Lymphoma, as well as how they intersect with chemical problems. Her Oncology research incorporates elements of Cancer, Cyclophosphamide, Fludarabine, Chemoimmunotherapy and Blinatumomab. As part of the same scientific family, Susan O'Brien usually focuses on Leukemia, concentrating on Bruton's tyrosine kinase and intersecting with Dose–response relationship.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment

Bruce D. Cheson;John M. Bennett;Michael Grever;Neil Kay.
Blood (1996)

2963 Citations

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn.
The New England Journal of Medicine (2013)

2148 Citations

Dasatinib in Imatinib-Resistant Philadelphia Chromosome–Positive Leukemias

Moshe Talpaz;Neil P. Shah;Hagop M Kantarjian;Nicholas Donato.
The New England Journal of Medicine (2006)

1987 Citations

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

Richard R. Furman;Jeff P. Sharman;Steven E. Coutre;Bruce D. Cheson.
The New England Journal of Medicine (2014)

1737 Citations

The biology of chronic myeloid leukemia

Stefan Faderl;Moshe Talpaz;Zeev Estrov;Susan O'Brien.
The New England Journal of Medicine (1999)

1578 Citations

Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

Hagop M Kantarjian;Francis Giles;Lydia Wunderle;Kapil Bhalla.
The New England Journal of Medicine (2006)

1542 Citations

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

J. C. Byrd;J. R. Brown;Susan O'Brien;J. C. Barrientos.
The New England Journal of Medicine (2014)

1470 Citations

Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien.
Blood (1997)

1458 Citations

Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

I F Khouri;M Keating;M Körbling;D Przepiorka.
Journal of Clinical Oncology (1998)

1424 Citations

Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

Michael J. Keating;Susan O'Brien;Maher Albitar;Susan Lerner.
Journal of Clinical Oncology (2005)

1238 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Susan O'Brien

Hagop M. Kantarjian

Hagop M. Kantarjian

The University of Texas MD Anderson Cancer Center

Publications: 779

Jorge E. Cortes

Jorge E. Cortes

Augusta University

Publications: 538

John C. Byrd

John C. Byrd

University of Cincinnati

Publications: 309

Elias Jabbour

Elias Jabbour

The University of Texas MD Anderson Cancer Center

Publications: 289

Farhad Ravandi

Farhad Ravandi

The University of Texas MD Anderson Cancer Center

Publications: 257

Michael Hallek

Michael Hallek

University of Cologne

Publications: 246

Guillermo Garcia-Manero

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center

Publications: 246

Andreas Hochhaus

Andreas Hochhaus

Friedrich Schiller University Jena

Publications: 211

Tadeusz Robak

Tadeusz Robak

Medical University of Lodz

Publications: 211

Francis J. Giles

Francis J. Giles

National University of Ireland, Galway

Publications: 196

Michele Baccarani

Michele Baccarani

University of Bologna

Publications: 188

Stephan Stilgenbauer

Stephan Stilgenbauer

University of Ulm

Publications: 170

Giovanni Martinelli

Giovanni Martinelli

University of Bologna

Publications: 169

Michael J. Keating

Michael J. Keating

The University of Texas MD Anderson Cancer Center

Publications: 168

Elihu H. Estey

Elihu H. Estey

Fred Hutchinson Cancer Research Center

Publications: 165

Richard A. Larson

Richard A. Larson

University of Chicago

Publications: 156

Something went wrong. Please try again later.